Two of the biggest stories in medicine this year — the arrival of the first disease-modifying treatments in Alzheimer’s and the stunning transformations made possible by new weight-loss drugs — have something in common: Eli Lilly & Co.

By the end of 2023, the Indianapolis-based company is expected to get the Food and Drug Administration’s nod for both its amyloid-targeting Alzheimer’s treatment donanemab and the obesity drug tirzepatide, which it already markets for diabetes as Mounjaro. Both represent multi-billion-dollar opportunities for Lilly, and have propelled the company’s stock steadily upward. A decade ago, it didn’t even break the top 10 pharma companies based on its market cap; today, it often leads the pack.

ncG1vNJzZmivp6x7o7jOqKSbnaKce6S7zGimqaGenryve8Crq6KbnJrAcH6Pa2pmaGdigHJ7w6usoKtdm7yzec6bnKyhpK56orrDZpilspiatq6x0WaqZqiipL2muMuem2adnJ56rbXLpbBmrJ9iwamxjK2mqQ%3D%3D